Cargando…

Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity

BACKGROUND. Prodrug-activator gene therapy with Toca 511, a tumor-selective retroviral replicating vector (RRV) encoding yeast cytosine deaminase, is being evaluated in recurrent high-grade glioma patients. Nonlytic retroviral infection leads to permanent integration of RRV into the cancer cell geno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiraoka, Kei, Inagaki, Akihito, Kato, Yuki, Huang, Tiffany T., Mitchell, Leah A., Kamijima, Shuichi, Takahashi, Masamichi, Matsumoto, Hiroshi, Hacke, Katrin, Kruse, Carol A., Ostertag, Derek, Robbins, Joan M., Gruber, Harry E., Jolly, Douglas J., Kasahara, Noriyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Basic and Translational Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5574670/ https://www.ncbi.nlm.nih.gov/pubmed/28387831 http://dx.doi.org/10.1093/neuonc/nox038

Ejemplares similares

Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model
por: Mitchell, Leah A., et al.
Publicado: (2017)

Radio-sensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector
por: Takahashi, Masamichi, et al.
Publicado: (2014)

Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector
por: Ostertag, Derek, et al.
Publicado: (2012)

Retroviral Replicating Vector Toca 511 (Vocimagene Amiretrorepvec) for Prodrug Activator Gene Therapy of Lung Cancer
por: Kushiya, Hiroki, et al.
Publicado: (2022)

A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models
por: Yagiz, Kader, et al.
Publicado: (2017)

Maintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids
por: Burnett, Ryan, et al.
Publicado: (2014)

THER-06. THERAPEUTIC EFFICACY OF RRV-MEDIATED PRODRUG ACTIVATOR GENE THERAPY IN CLINICAL TRIALS OF RECURRENT HIGH-GRADE GLIOMA AND IN MURINE ORTHOTOPIC MODELS OF INTRACEREBRAL GLIOMA AND INTRACEREBELLAR MEDULLOBLASTOMA
por: Richardson, Angela, et al.
Publicado: (2020)

Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors (RRV) in a rodent brain tumor model
por: Yin, Dali, et al.
Publicado: (2013)

Dual-vector prodrug activator gene therapy using retroviral replicating vectors
por: Kubo, Shuji, et al.
Publicado: (2018)

Efficient tumor transduction and antitumor efficacy in experimental human osteosarcoma using retroviral replicating vectors
por: Kubo, Shuji, et al.
Publicado: (2018)

On the Therapeutical Value of the Injection of Medicated Fluids through the Eustachian Tube
por: Gruber, Jos., et al.
Publicado: (1881)

The retinoid anticancer signal: mechanisms of target gene regulation
por: Liu, T, et al.
Publicado: (2005)

Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity
por: Rephaeli, A, et al.
Publicado: (2007)

Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration
por: Lee, C M, et al.
Publicado: (2006)

In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells
por: Jiang, P, et al.
Publicado: (2014)

Anticancer efficacy of cisplatin and trichostatin A or 5-aza-2′-deoxycytidine on ovarian cancer
por: Meng, F, et al.
Publicado: (2013)

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
por: van Leeuwen, R W F, et al.
Publicado: (2013)

Camptothecin suppresses NRF2–ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs
por: Chen, Feng, et al.
Publicado: (2017)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
por: Lin, Amy H., et al.
Publicado: (2017)

Cryptic transcripts from a ubiquitous plasmid origin of replication confound tests for cis-regulatory function
por: Lemp, Nathan A., et al.
Publicado: (2012)

The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo
por: Akashi, Y, et al.
Publicado: (2007)

p53-dependent and p53-independent anticancer effects of different histone deacetylase inhibitors
por: Sonnemann, J, et al.
Publicado: (2014)

Pharmacologically directed strategies in academic anticancer drug discovery based on the European NCI compounds initiative
por: Hendriks, Hans R, et al.
Publicado: (2017)

Retroviral Replicating Vectors Mediated Prodrug Activator Gene Therapy in a Gastric Cancer Model
por: Fujino, Hiroaki, et al.
Publicado: (2023)

Durable Control of Autoimmune Diabetes in Mice Achieved by Intraperitoneal Transplantation of “Neo‐Islets,” Three‐Dimensional Aggregates of Allogeneic Islet and “Mesenchymal Stem Cells”
por: Westenfelder, Christof, et al.
Publicado: (2017)

The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation
por: Isham, C R, et al.
Publicado: (2012)

Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma
por: Horie, N, et al.
Publicado: (2007)

Adenovirus-mediated hypoxia-targeting cytosine deaminase gene therapy enhances radiotherapy in tumour xenografts
por: Liu, J, et al.
Publicado: (2007)

Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymphendothelial gap formation in vitro
por: Madlener, S, et al.
Publicado: (2010)

Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models
por: Cao, S, et al.
Publicado: (2014)

Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells
por: Tomimaru, Y, et al.
Publicado: (2010)

Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1
por: Akashi, Y, et al.
Publicado: (2014)

Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling
por: Fetoni, A R, et al.
Publicado: (2015)

Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiol
por: Shen, Yu-chi, et al.
Publicado: (2015)

Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy
por: Harada, H, et al.
Publicado: (2009)

Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01
por: Yeow, W-S, et al.
Publicado: (2006)

Ursodeoxycholic acid attenuates the expression of proinflammatory cytokines in periodontal cells
por: Talebian, Reza, et al.
Publicado: (2020)

Approaches to enhancing the retroviral transduction of human synoviocytes
por: Del Vecchio, Maria A, et al.
Publicado: (2001)

Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer
por: Anker, Jonathan, et al.
Publicado: (2023)

Differential Targeting of Stem Cells and Differentiated Glioblastomas by NK Cells
por: Tseng, Han-Ching, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4r7bnklbegq039j991rpitkqb1